(Total Views: 610)
Posted On: 03/26/2018 12:31:33 PM
Post# of 72443
i would have thought the vast majority of patients in this long trial were finished prior to Nov. By Dec I thought just a mere handful of patients were still waiting for their final 4 week post treatment visit. That means data on all but a few should have been getting wrapped up long before the trial officially ended in late Dec. CRO should have been checking in on the sites to establish how far along they were as many must have had only a handful of patients since we had 33 sites or so.
If we are to say this time is nothing out of the ordinary to merely collect the final data and tabulate it (unless they have but one adding machine) then the analyzing could take months. I heard nothing from the many solid medical types on any board say that we were looking at 6 months or so to get top line results back in late 2017. If that was expected, mgt sure could have helped out by providing some rough guidelines as to timing.
The only strong caution I heard was from you that the analyzing of the data could take quite some time to make sure no mistakes are made. I can accept that, the tabulation end though seems way overdue.
But then I have no clinical trials experience so I just add it up as another learning point.
I know there must have been a lot of buying in Feb and Mar by those unaware of the time delay so many are left in the red since buying could have been delayed another month or two since results are still not on the real near horizon (as in 6 weeks or less) IMO.
Not really ticked off, just venting how continually I (and likely others) have misplayed the time line necessary to buy at the right time.
No more negative posts forthcoming from me.
If we are to say this time is nothing out of the ordinary to merely collect the final data and tabulate it (unless they have but one adding machine) then the analyzing could take months. I heard nothing from the many solid medical types on any board say that we were looking at 6 months or so to get top line results back in late 2017. If that was expected, mgt sure could have helped out by providing some rough guidelines as to timing.
The only strong caution I heard was from you that the analyzing of the data could take quite some time to make sure no mistakes are made. I can accept that, the tabulation end though seems way overdue.
But then I have no clinical trials experience so I just add it up as another learning point.
I know there must have been a lot of buying in Feb and Mar by those unaware of the time delay so many are left in the red since buying could have been delayed another month or two since results are still not on the real near horizon (as in 6 weeks or less) IMO.
Not really ticked off, just venting how continually I (and likely others) have misplayed the time line necessary to buy at the right time.
No more negative posts forthcoming from me.
(2)
(0)
Scroll down for more posts ▼